The Medical Letter on Drugs and Therapeutics
Transcatheter Aortic-Valve Replacement
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Transcatheter aortic-valve replacement (TAVR), a procedure in which a prosthetic valve is inserted into the aortic annulus by a catheter, has been approved by the FDA as an alternative to surgical aortic-valve replacement for patients with severe symptomatic aortic stenosis who are considered inoperable.

AORTIC STENOSIS — Untreated patients with symptomatic aortic stenosis have a 50% mortality rate within 2 years. Some patients with severe aortic stenosis are not candidates for surgery because of advanced age, left ventricular dysfunction or other illnesses.1 Others undergo surgery despite a high operative risk.

THE VALVE — The Edwards SAPIEN transcatheter heart valve (Edwards Lifesciences) approved in the US is a trileaflet valve constructed from bovine pericardium and mounted in a balloon-expandable stainless steel frame. The ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Transcatheter Aortic-Valve Replacement
Article code: 1388b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian